1 INDICATIONS AND USAGE Losartan potassium and hydrochlorothiazide tablets USP are a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: Â· Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Â· Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programâ€™s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets USP may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets USP are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2)].
alembic pharmaceuticals inc.
16 HOW SUPPLIED/STORAGE AND HANDLING
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE Tablets USP are supplied as.
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE Tablets USP 50 mg/12.5 mg: yellow coloured, tear drop shaped, biconvex film coated tablets debossed with â€˜L146â€™ on one side and plain on other side. NDC 62332-048-30 bottle of 30 tablets NDC 62332-048-90 bottle of 90 tablets NDC 62332-048-91 bottle of 1000 tablets NDC 62332-048-10 carton of 10 blisters of 10 tablets
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE Tablets USP 100 mg/12.5 mg: white coloured, oval shaped, biconvex film coated tablets debossed with â€˜L144â€™ on one side and plain on other side. NDC 62332-049-30 bottle of 30 tablets NDC 62332-049-90 bottle of 90 tablets NDC 62332-049-91 bottle of 1000 tablets NDC 62332-049-10 carton of 10 blisters of 10 tablets
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE Tablets USP 100 mg/25 mg: yellow coloured, tear drop shaped, biconvex film coated tablets debossed with â€˜L145â€™ on one side and plain on other side. NDC 62332-050-30 bottle of 30 tablets NDC 62332-050-90 bottle of 90 tablets NDC 62332-050-91 bottle of 1000 tablets NDC 62332-050-10 carton of 10 blisters of 10 tablets Storage Store at 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [See USP Controlled Room Temperature]. Keep container tightly closed. Protect from light.
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site